Brief: TARA-002 Demonstrates 68% Complete Response Rate At Six Months In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Protara Therapeutics

23/02/2026 22:28

Feb 23 (Reuters) - Protara Therapeutics Inc TARA.O:

TARA-002 DEMONSTRATES 68% COMPLETE RESPONSE RATE AT SIX MONTHS IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER

PROTARA THERAPEUTICS INC: EXPECTS TO COMPLETE ENROLLMENT OF BCG-UNRESPONSIVE COHORT OF ADVANCED-2 TRIAL IN 2H 2026

PROTARA THERAPEUTICS INC: FAVORABLE SAFETY AND TOLERABILITY PROFILE WITH NO GRADE 3 OR GREATER TREATMENT-RELATED ADVERSE EVENTS

PROTARA THERAPEUTICS INC: REMAINS ON TRACK TO INITIATE ADVANCED-3 REGISTRATIONAL TRIAL IN BCG-NAÏVE PATIENTS IN SECOND HALF OF 2026

Source text: ID:nGNX7jnkmz

Further company coverage: TARA.O

 ((Reuters.Briefs@thomsonreuters.com;))